# Lyell Immunopharma (LYEL) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/LYEL
## Company Profile
- Ticker: LYEL
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: 13.45 USD
- Market cap: 347444555.43 USD
- Last updated: 2026-08-05
## Business Overview
### Next-Generation CAR-T Therapies
Lyell Immunopharma develops engineered CAR-T cell therapies intended to improve response depth, durability and activity in hematologic and solid tumors.
### Ronde-cel
Ronde-cel is an autologous CAR-T product with an OR-gated design targeting either CD19 or CD20. Its manufacturing process enriches less-differentiated T cells to support persistence in large B-cell lymphoma.
### Pivotal LBCL Programs
PiNACLE is a pivotal single-arm study in third- or later-line large B-cell lymphoma. PiNACLE-H2H is a randomized Phase 3 trial comparing ronde-cel directly with established CD19 CAR-T therapies in second-line disease.
### LYL273
LYL273 is a separate engineered cell therapy in Phase 1 development for metastatic colorectal cancer, extending Lyell's platform into solid tumors.
## Why The Stock Is Moving

The latest monitored company update is “Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Additional PiNACLE data in the second half of 2026.
- LYL273 safety update in the first half of 2026 and clinical-outcomes update in the second half of 2026.
- Pivotal PiNACLE data around mid-2027, followed by a planned BLA submission in 2027.

## Recent News
- 2026-08-06 20:05 EST — [Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-sec-9330d763) — Source: Lyell Immunopharma
- 2026-06-25 12:00 EST — [Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-h-c-wainwright-4th-annual-cell-the-25f96787) — Source: Lyell Immunopharma
- 2026-06-12 16:45 EST — [Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-presents-updated-safety-data-and-translational-insights-for-r-248fa339) — Source: Lyell Immunopharma
- 2026-06-08 10:00 EST — [Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-provides-update-on-safety-profile-of-lyl273-in-relapsed-or-re-56a2333e) — Source: Lyell Immunopharma
- 2026-06-04 20:05 EST — [Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-to-present-phase-1-2-safety-and-translational-data-for-ronde--049c6b7a) — Source: Lyell Immunopharma